Divis Laboratories’ Unit-I at Choutuppal in state of Telangana has been inspected by the United States Food & Drug Administration (USFDA) from May 14 to May 16, 2018. This was a general cGMP inspection by the USFDA. The inspection has been concluded with no 483 observations.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.